Tamoxifen a new therapeutic approach for allergy airway disease
-
1
Universidad Austral de Chile, Chile
Recurrent airway obstruction (RAO) is an asthma-like condition that develops in mature horses following stabling and exposure to dusty hay and straw. The hallmark of this disease is that hay/straw exposure induces clinical airway obstruction, airway neutrophilia and increased airway mucous production. Our previous study indicated that tamoxifen has the ability to induce apoptosis in vitro in granulocytic cells from peripheral blood and broncheoalveolar lavage fluid (BALF). Therefore, we propose that tamoxifen, when used as a treatment in RAO-affected horses, induces a resolution of allergy airway inflammation through action on polymorphonuclear neutrophils. For this purpose, nine RAO-susceptible horses sensitized to Aspergillus fumigatus (RAO herd) will be selected for use in this study. The animals will be exposed to dusty/moldy hay, and once the signs of the disease appear. Later, the horses will be treated with 100 mg PO of tamoxifen every other day in a remission environment. During treatment and after drug administration has ended, periodical evolution of RAO clinical signs will be conducted to evaluate the effect of tamoxifen on airway inflammation (clinical score, mucus score, endoscopic examination and BALF for apoptosis evaluation). Our results indicate that RAO-affected horses treated with tamoxifen displayed a significant reduction of neutrophils in BALF and a concomitant improvement in their clinical status. This reduction in neutrophils BALF is related to the percentage of cells positive Anexin-V. These results indicate that the apoptotic mechanisms under these experimental conditions would affect blood and BALF granulocytic cells, particularly in early apoptosis (positive Anexin–V).
Acknowledgements
FONDECYT 1130355
Keywords:
Tamoxifen,
allergy,
Airway Obstruction,
Inflammation,
Neutrophils
Conference:
15th International Congress of Immunology (ICI), Milan, Italy, 22 Aug - 27 Aug, 2013.
Presentation Type:
Abstract
Topic:
Immune-mediated disease pathogenesis
Citation:
Moran
G,
Folch
H,
Perez
B,
Morales
N,
Sarmiento
J,
Henriquez
C and
Galecio
J
(2013). Tamoxifen a new therapeutic approach for allergy airway disease.
Front. Immunol.
Conference Abstract:
15th International Congress of Immunology (ICI).
doi: 10.3389/conf.fimmu.2013.02.00082
Copyright:
The abstracts in this collection have not been subject to any Frontiers peer review or checks, and are not endorsed by Frontiers.
They are made available through the Frontiers publishing platform as a service to conference organizers and presenters.
The copyright in the individual abstracts is owned by the author of each abstract or his/her employer unless otherwise stated.
Each abstract, as well as the collection of abstracts, are published under a Creative Commons CC-BY 4.0 (attribution) licence (https://creativecommons.org/licenses/by/4.0/) and may thus be reproduced, translated, adapted and be the subject of derivative works provided the authors and Frontiers are attributed.
For Frontiers’ terms and conditions please see https://www.frontiersin.org/legal/terms-and-conditions.
Received:
08 Mar 2013;
Published Online:
22 Aug 2013.
*
Correspondence:
Dr. Gabriel Moran, Universidad Austral de Chile, Valdivia, Chile, gmoran@uach.cl